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ABSTRACT
Thrombotic microangiopathy (TMA) is one of the most severe complications of stem cell transplantation
(SCT). Endothelial cell injury caused by the toxic effects of high-dose chemoradiotherapy is likely the primary
event in pathogenesis. The incidence, clinical settings, and risk factors for TMA in the era of nonmyeloablative
conditioning have not been well defined. The data on 147 consecutive SCTs in a single center were collected,
and patients with TMA were identified. Patient characteristics, response to therapy, and outcome were
recorded, and risk factors were determined. TMA occurred in 22 of 147 transplantations, with a projected
incidence of 20%  4%. TMA occurred in 3 clinical settings: classic multifactorial TMA, TMA associated with
severe hepatic graft-versus-host disease (GVHD), and TMA associated with second SCT, with a projected
incidence of 8%  3%, 73%  14%, and 70%  16% of patients at risk, respectively. TMA occurred after 23%
 6% of nonmyeloablative and 16%  5% of myeloablative conditioning regimens (not significant). Univariate
analysis determined SCT from unrelated donors, SCT during advanced or active disease, second SCT within
6 months of a prior SCT, and acute GVHD as risk factors for TMA. The last 2 factors remained significant in
a multivariate model. Thirty-two percent of patients responded to therapy. The peri-TMA mortality rate was
68%  10%. Six patients had diffuse alveolar hemorrhage complicating TMA. SCT-associated TMA is a
relatively common complication with unsatisfactory therapy and grim prognosis. Fludarabine-based nonmy-
eloablative conditioning does not confer a lesser risk for TMA. This observation may relate to the selective use
of these regimens in elderly and heavily pretreated patients or to the lack of reduction of GVHD with these
regimens, and fludarabine itself may be involved in causing endothelial damage. Further exploration of novel
preventive and therapeutic measurements is required in high-risk settings.
© 2004 American Society for Blood and Marrow Transplantation
KEY WORDS
Thrombotic microangiopathy ● Stem cell transplantation ● NonmyeloablativeI
A
m
m
p
a
t
l
d
pNTRODUCTION
Thrombotic microangiopathy (TMA) is charac-
erized by the classic clinical pentad of thrombocyto-
enia, microangiopathic hemolytic anemia, neuro-
ogic abnormalities, renal abnormalities, and fever [1]
esulting from the formation of widespread platelet
hrombi within the microvasculature. Classic idio-
athic TMA is associated with severe deﬁciency or
nhibition of the plasma metalloprotease ADAMTS13
2-4]. This protease speciﬁcally cleaves von Wille-
rand factor, thus reducing its multimeric size. a
84diopathic TMA is characterized by inhibition of
DAMTS13 by an autoantibody, thus causing accu-
ulation of unusually large von Willebrand factor
ultimers, which are implicated in the formation of
latelet aggregates [4]. TMA is one of the most severe
nd devastating complications of stem cell transplan-
ation (SCT) [5-17]. SCT-associated TMA is not re-
ated to ADAMTS13 deﬁciency [7,18-19]; rather, en-
othelial cell injury is likely the primary event in the
athogenesis [6,20].
Multiple factors contribute to endothelial damagefter SCT. The initial endothelial injury is induced by
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Posttransplantation TMA
Bhe toxic effects of high-dose chemotherapy and total
ody irradiation given during pre-SCT conditioning.
owever, TMA is much more common after alloge-
eic SCT, occurring on average after 5% to 15% of
CTs, compared with less than 1% after autologous
CT [5-17]. The clinical severity is also higher after
llogeneic SCT, for which TMA-associated mortality
s on the average 50%, compared with 26% in the
utologous setting [6]. Factors associated with alloge-
eic SCT—such as the use of cyclosporin A, acute
raft-versus-host disease (GVHD), cytokine release
yndromes, and infections such as with cytomegalovi-
us (CMV) or fungi [21]—may perpetuate endothelial
ell injury and enhance the appearance of TMA. In
articular, the use of cyclosporin A may have a central
ole in the pathogenesis of SCT-associated TMA.
he importance of cyclosporine is documented by the
bservation of TMA after solid organ transplantation
n association with its use, although this occurs with a
ower incidence of approximately 5% [22]. Cyclospor-
ne may cause direct endothelial injury [6,20,23] and
ay also have procoagulant activity because of in-
reased platelet aggregation and vasoconstriction
aused by a variety of effects on vascular endothelium
nd platelets [7]. Inﬂammatory cytokines involved in
VHD may mediate vascular endothelial cell injury
r procoagulant activity, and the endothelial cell itself
ay become a target of GVHD [7].
Reduced-intensity or nonmyeloablative condi-
ioning regimens have been recently introduced into
linical practice. These regimens were designed to
llow some tumor cytoreduction, as well as sufﬁcient
mmunosuppression to promote allograft engraftment
nd the induction of a graft-versus-malignancy effect
s the primary curative therapeutic goal [24,25]. Non-
yeloablative SCT (NST) is less toxic, thus allowing
he treatment of older patients and patients with co-
orbidities not eligible for standard ablative condi-
ioning. The relative toxicities, GVHD rates, and
verall outcome with these regimens still need to be
eﬁned. Because toxic effects of the conditioning reg-
men have a central role in the pathogenesis of SCT-
ssociated TMA, it is conceivable that TMA risk after
ST will markedly decrease. This study was designed
o evaluate the risk factors and clinical settings of
MA in the era of NST, and the results showed that
MA risk did not decrease.
ATIENTS AND METHODS
atient Identification
Data on all allogeneic transplantations from July
, 2000, in a single transplant center were prospec-
ively recorded, and a data set for patients with SCT-
ssociated TMA was established. A total of 147 allo-
eneic transplants were given to 132 patients with c
B&MTarious hematologic malignancies during this period.
ifteen patients treated for posttransplantation relapse
ith intensive chemotherapy (either ablative or non-
yeloablative) and mobilized donor lymphocytes with
tem cells were considered as having a second SCT.
atients given nonmobilized donor lymphocyte infu-
ions were not considered as having a second SCT.
hirty-three patients had at least 1 prior SCT (autol-
gous or allogeneic). The diagnostic criteria for TMA
ncluded thrombocytopenia; either a decreasing plate-
et count or a failure to achieve platelet engraftment;
nd microangiopathic hemolysis, as evidenced by in-
reased lactate dehydrogenase (LDH) and fragmented
ed blood cells observed in peripheral blood ﬁlm.
eurologic symptoms and renal abnormalities sup-
orted the diagnosis but were not required. At the
ime of writing, the data set included 22 patients
iagnosed with TMA after SCT.
onditioning Regimens
Sixty-three SCTs were considered to follow my-
loablative conditioning: busulfan/cyclophosphamide
n  37); cyclophosphamide/total body irradiation
n  15); carmustine, etoposide, cytarabine, and mel-
halan (n  7); or high-dose melphalan (n  4). The
onditioning regimen was selected on the basis of the
nderlying malignancy. Patients not eligible for stan-
ard ablative SCT because of advanced age, comor-
idities, or extensive prior therapy (including prior
CT) and patients with chronic myeloid leukemia
CML) in ﬁrst chronic phase were eligible for non-
yeloablative conditioning. Eighty-four SCTs fol-
owed a reduced-intensity regimen that consisted of a
ombination of ﬂudarabine and intravenous busulfan
n 29) or melphalan (n 41) or other combinations
n  14) based on the underlying malignancy. The
llograft source was peripheral blood stem cells in
ost SCTs (n  144) and bone marrow in a minority
f SCTs (n  3). GVHD prophylaxis consisted
niformly of cyclosporine and a short course of meth-
trexate. Patients with a matched unrelated or mis-
atched related donor SCT were given antithymo-
yte globulin during conditioning. Ex vivo T-cell
epletion was not used. Standard institutional sup-
ortive care guidelines were followed. Acute and
hronic GVHD was diagnosed, staged, and graded on
he basis of standard criteria. Chimerism was assessed
pproximately 1 month after SCT by ﬂuorescent in
itu hybridization analysis for X and Y markers in
ex-mismatched SCT and by microsatellite analysis in
ex-matched SCT [26].
efinitions
Disease status was determined before SCT ac-
ording to standard criteria. Early disease status in-
luded acute leukemia in ﬁrst complete remission,
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4ML in ﬁrst chronic phase, multiple myeloma, and
ymphoma in ﬁrst remission. All other disease phases
ere considered advanced disease. Patients were de-
ermined as having disease in remission if they had no
vidence of disease by standard criteria. In patients
ith acute leukemia, this required less than 5% blasts
n marrow aspirate and normal blood counts. For the
urpose of this analysis, patients with CML in chronic
hase were included with those in remission.
Complete response to therapy of TMA required
esolution of symptoms attributed to TMA, increase
f platelet count to 50  109/L, and normalization
f LDH. Partial response required improvement in
hese parameters that was not sufﬁcient to determine
omplete response.
tatistical Analysis
The incidence of TMA was calculated and plotted
y using Kaplan-Meier analysis [27]. Patients were
ensored at the time of last follow-up or death or at
he start of conditioning for a second SCT. Categor-
cal risk factors for TMA incidence were compared by
sing the log-rank test. Variables found signiﬁcant in
he univariate analysis were included in a Cox propor-
ional hazard model. Overall survival was calculated
rom the day of diagnosis of TMA and was plotted
ith Kaplan-Meier analysis.
ESULTS
atient Characteristics at Diagnosis
TMA was diagnosed in 22 patients after allogeneic
CT. The disease and patient characteristics at the
ime of diagnosis of TMA are outlined in Table 1.
he median age at diagnosis was 43 years (range,
1-57 years). There were 17 men and 5 women with a
iagnosis of acute myeloid (n  10) or lymphoid (n 
) leukemia, non-Hodgkin lymphoma (n  3), multi-
le myeloma (n  3), or CML (n  1). The donors
ere HLA-matched siblings (n  12) or matched
nrelated donors (n  10). Fourteen patients had
MA after NST, and 8 had TMA after ablative SCT.
MA was diagnosed a median of 30 days after SCT
range, 12-390 days). All patients were thrombocyto-
enic at the time of diagnosis, with a median platelet
ount of 14  109/L (range, 3-39  109/L). Ten
atients had rapidly decreasing platelet counts, and in
2 patients, TMA was diagnosed before platelet en-
raftment. All patients had evidence of microangio-
athic hemolysis, as evidenced by fragmented red
lood cells in peripheral blood ﬁlm. All patients had
ncreased LDH (median, 716 IU/L [range, 390-1205
U/L] and 967 IU/L [range, 481-7276 IU/L] at diag-
osis and maximally during the course, respectively
normal institutional level, 100-260 IU/L]). The me-
ian bilirubin level was 3.3 mg/dL (range, 1.5-64.5 m
86g/dL) and 16.1 mg/dL (range, 2.8-64.9 mg/dL) at
iagnosis and maximally during the course, respec-
ively. The median creatinine level was 1.3 mg/dL
range, 0.7-4.9 mg/dL), and only 3 patients had a
reatinine level 2 mg/dL. Six patients had excessive
yclosporine levels within 1 week before diagnosis,
nd 4 patients were off cyclosporine therapy at the
ime of diagnosis of TMA. Eleven patients had neu-
ologic symptoms during the course, such as confu-
ion or changes in consciousness. However, most of
hese patients had multiple other potentially contrib-
ting factors (in particular, liver failure), and in only 2
atients (Table 1; patients 2 and 7) was neurologic
ysfunction thought to be predominantly related to
MA. Fever was not considered a diagnostic criterion.
ost patients had infections at or before diagnosis of
MA and were treated with antibiotics, but only 1
atient (patient 15) had a documented disseminated
ungal infection. CMV reactivation was common but
as not related in timing to TMA diagnosis.
linical Settings and Predicting Factors
TMA occurred in 22 (15%) of 147 SCTs, with a
rojected incidence of 20%  4% (Figure 1). TMA
as diagnosed in 3 overlapping clinical settings. Nine
atients had classic multifactorial TMA (Table 1; pa-
ients 1-9). The projected incidence was 8% 3%. In
cases, TMA occurred in patients previously diag-
osed with severe (stage III-IV) hepatic acute GVHD
bilirubin6 mg/dL) at the time of diagnosis of TMA
Table 1; patients 10-18). All of these patients, as well
s 2 additional patients with less than stage III hepatic
VHD at diagnosis (patients 8 and 9, who belonged
o the classic posttransplantation TMA group), had
rogressive jaundice (bilirubin 15 mg/dL, believed
o predominantly result from GVHD) during the
ourse. Overall, TMA was diagnosed during the
ourse of severe hepatic GVHD in 11 of 15 patients,
r at a projected risk reaching 73%  14%. Seven
atients had TMA during the course of a second
llogeneic SCT for post-SCT relapse, all from the
riginal donor (Table 1; patients 16-22). Three of
hese patients also had severe hepatic GVHD that
verlapped with the hepatic GVHD-associated TMA
ariant (patients 16-18). TMA occurred during 7 of 15
econd allogeneic SCTs, with a projected risk as high
s 70%  16%.
When all SCTs were considered, the univariate
nalysis identiﬁed SCT from an unrelated donor,
CT during advanced or active disease, a prior abla-
ive SCT (allogeneic, autologous, or both) within 6
onths before the current SCT (Figure 2), and acute
VHD as factors associated with the occurrence of
CT-associated TMA (Table 2). Male sex had bor-
erline signiﬁcance. A multivariate Cox regression
odel determined that acute GVHD and a second
T*
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
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Posttransplantation TMA
Bable 1. Patient Characteristics at Diagnosis of TMA
Patient
No. TMA Type*
Age (y)/
Sex
Disease
Status† Donor‡
Prior
SCT§
Conditioning
Regimen
Acute
GVHD¶ PLT#
LDH
Diag/Max
(IU/L)**
Bilirubin
Diag/Max**
(mg/dL)
Cr††
(mg/dL)
CSA‡‡
(g/L)
Neurologic
Findings
1 Classic 49/M ALL
ref rel
Sib No NST
FM
GrII
GI
16 630/757 3.8/4.2 1.2 209 No
2 Classic 44/F AML
1 ref
MUD No NST
FB
No 17 786/903 2.6/4.7 1.5 376 Yes
3 Classic 53/M MM Sib Auto >6
mo
NST
FM
GrII
Gl
25 1205/7276 1.7/17.6 1.8 295 No
4 Classic 50/F MDS Sib No Ablative
BuCy
GrIII
Gl
11 1082/1082 1.7/11.9 0.9 462 No
5 Classic 57/M MM Sib Auto >6
mo
NST
FM
No 11 523/804 1.9/2.8 1.6 289 No
6 Classic 22/M AML
ref rel
MUD Auto <6
mo
NST
FM
No 7 730/847 2.5/2.9 1.5 490 No
7 Classic 56/M NHL ref MUD Auto <6
mo
NST
FM
GrI
s
31 569/961 1.5/3.2 2.5 356 Yes
8 Classic/hepatic 50/M NHL
ref
Sib No Ablative
BEAM
GrIV
s, liv, Gl
7 570/1459 2.5/25.7 1.3 190 Yes
9 Classic/hepatic 52/M NHL
ref
MUD Auto >6
mo
NST
FM
GrIV
liv, Gl
14 480/781 1.7/32.7 1.0 191 Yes
10 Hepatic 45/M ALL
CR3
MUD Auto <6
mo
NST
F/low TBI
GrIV
liv, Gl
20 845/1721 14.9/27 1.3 727 Yes
11 Hepatic 40/M 2AML
untreat
MUD No Ablative
BuCy
GrIV
liv, Gl
9 670/818 32.4/44.7 1.1 541 Yes
12 Hepatic 34/M CML
CP
MUD No Ablative
BuCy
GrIV
s, liv, Gl
3 507/1522 31.6/34.6 0.8 48 Yes
13 Hepatic 33/M MM
ref
MUD Auto <6
mo
NST
FM
GrIV
liv, Gl
16 804/990 12.6/16.5 4.9 453 Yes
14 Hepatic 37/M AML
CR2
Sib No Ablative
BuCy
GrIV
s, liv, Gl
14 729/986 6.2/16.1 1.0 259 No
15 Hepatic 28/M AML
CR2
MUD No NST
FM
GrIV
liv
19 415/510 64.5/64.9 1.3 81 Yes
16 Hepatic/2 allo 51/M AML
pt-relapse
MUD Allo <6
mo
NST
FB
GrIV
liv, Gl
39 388/967 6.6/27.9 1.5 0 Yes
17 Hepatic/2 allo 45/M AML
pt-relapse
Sib Allo <6
mo
Ablative
HD mel
GrIV
liv, Gl
11 402/481 6.6/14.5 1.9 265 Yes
18 Hepatic/2 allo 33/F AML
pt-relapse
Sib Allo <6
mo
NST
FA/ida
GrIV
s, liv, Gl
19 861/1142 10.4/27 0.7 0 No
19 2 allo 21/M ALL
pt-relapse
Sib Allo <6
mo
NST
Mit/hidac
No 21 716/1540 3.3/7.4 3.0 0 No
20 2 allo 42/M AML
pt-relapse
Sib Allo <6
mo
NST
Mit/hidac
GrIII
Gl
13 751/751 5.7/5.7 1.2 585 No
21 2 allo 23/F ALL
pt-relapse
Sib Allo <6
mo
Ablative
HD mel
GrII
s, Gl
4 752/6087 2.4/16.4 0.9 119 No
22 2 allo 35/F ALL
pt-relapse
Sib Allo <6
mo
Ablative
HD mel
GrIII
Gl, liv
11 603/603 2.5/3.5 0.7 0 No
TMA indicates thrombotic microangiopathy; 2allo, second allogeneic transplantation.
ALL, acute lymphatic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-
Hodgkin lymphoma; ref, refractory; rel, relapse; CR, complete remission; CP, chronic phase, 1 ref, primary refractory; pt-relapse, post
transplantation relapse; untreat, previously untreated.
Sib, HLA-matched sibling; MUD, matched unrelated donor.
SCT, stem cell transplantation; auto, autologous; allo, allogeneic, /6 mo, more/less than 6 mo before current transplantation.
NST, nonmyeloablative stem cell transplantation; F, ﬂudarabine; M, melphalan; Bu, busulfan; Cy, cyclophosphamide; BEAM, carmustine,
etoposide, cytarabine, and melaphan; low TBI, total body irradiation 200 cG; A, cytarabine; ida, idarubicin; Mit, mitoxantrone; hidac,
high-dose cytarabine; HD mel, high-dose melaphan.
Gr, GVHD grade; Gl, gastrointestinal; liv, liver; s, skin.
PLT, platelet count at diagnosis (109/L).
*Diag/max, at diagnosis/maximally during the course.
†Cr, creatinine.
‡CSA, maximal cyclosporin A serum level during 1 wk before diagnosis.
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4CT within 6 months of a prior ablative SCT were
he only predicting factors (Table 3). The same factors
emained signiﬁcant even when second allogeneic
CTs were not included (data not shown).
omparison of NST and Myeloablative SCT
The risk of TMA after NST and myeloablative
onditioning was 23%  6% and 16%  5%, respec-
ively. Nonmyeloablative conditioning was therefore
ot associated with a lesser risk for TMA, and there
as even a non–statistically signiﬁcant trend for a
igher risk. Table 4 summarizes the differences in
atient characteristics and outcomes between the 2
ohorts. As expected by the treatment strategy, pa-
ients allocated to NST were older, more of them had
ymphoma or multiple myeloma rather than acute
eukemia, and more had had a recent prior SCT.
cute GVHD rates and severity and chimerism anal-
sis were similar between cohorts.
reatment and Outcome
The outcomes after diagnosis of TMA are out-
ined in Table 5. The initial treatment strategy was
ose reduction or complete withdrawal of cyclospor-
ne therapy (in 18 patients treated with cyclosporine at
he time of diagnosis) and transfusion of cryoprecipi-
ate-poor plasma. Four patients had a complete re-
ponse, and 1 had a partial response, for an overall
esponse rate of 23%. Four patients had therapeutic
lasma exchange (TPE) after the failure of prior ther-
py. One had complete response and 1 had a partial
esponse; 2 did not respond. One patient was treated
ith deﬁbrotide, with no response. The overall re-
ponse rate to all lines of therapy was 32%.
Four patients (18%) are currently alive and disease
igure 1. Cumulative incidence of thrombotic microangiopathy
TMA) after 147 allogeneic stem cell transplantations.ree. Eighteen patients died 2 to 227 days after the t
88nset of TMA. The Kaplan-Meier survival analysis
redicts an overall survival of 9%  8% (Figure 3).
owever, the peri-TMA mortality rate, where TMA
ay have caused or contributed to mortality, was 68%
10%. Ten patients died of complications of acute
VHD. In 4 patients, the primary cause of death was
iffuse alveolar hemorrhage (DAH), and 1 died of
entral nervous system bleeding. Two patients with
evere hepatic GVHD also had DAH as a contributing
ause of death. One patient died of cerebral TMA.
wo additional patients died of relapse. For the pur-
ose of this analysis, patients who had a second allo-
eneic SCT for post-SCT relapse and who died in
emission were not considered as dying of relapse.
ISCUSSION
TMA is a severe and relatively common compli-
ation after allogeneic SCT. It occurred in our study
ith an estimated risk of 20%  4% of all transplan-
ations. The reported incidence varies from 0.5% to
1.4% in different studies [5-17] but is on average 5%
o 15% [17]. This broad range of incidence is related
n part to lack of a uniform deﬁnition of SCT-associ-
ted TMA, small numbers of patients included in each
tudy, a wide range of differences in patient and SCT
haracteristics included in different studies, and, prob-
bly, underdiagnosis of this syndrome. The incidence
f TMA in this study was in the high reported range
or several reasons. First, we used a less strict deﬁni-
ion of TMA. The presence of thrombocytopenia and
icroangiopathy, as evidenced by the markedly in-
reased LDH and fragmented red blood cells ob-
erved in peripheral blood ﬁlm, in the absence of
igure 2. Cumulative incidence of thrombotic microangiopathy
TMA) after 147 allogeneic stem cell transplantations and a com-
arison of the incidence among patients with a history of recent (6
onths) allogeneic or autologous stem cell transplantation and
hose with no recent transplantation.
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Posttransplantation TMA
Blternative apparent etiologies, sufﬁced to make the
iagnosis of TMA. With the advent of effective ther-
py, this deﬁnition, rather than the classic pentad, is
ow widely accepted for the diagnosis of idiopathic
MA [28]. The diagnosis of TMA in SCT patients is
ifﬁcult and requires a high level of clinical suspicion
ecause its presentation overlaps with other post-SCT
omplications. Renal failure and neurologic symptoms
ay be related to other post-SCT conditions and are
ften absent at the time of diagnosis of TMA. In our
eries, renal failure was uncommon, and neurologic
ymptoms were thought to be related to TMA in only
able 2. Clinical Factors for Prediction of TMA*
Variable n
No. with
TMA
Projected
Incidence P Value
ll SCT 147 22 (15%) 20  4%
ge
<40 y 53 9 (17%) 22  7% NS
>40 y 94 13 (14%) 28  5%
ex
Male 87 17 (20%) 26  6% .06
Female 60 5 (8%) 11  5%
isease type
Acute leukemia 76 15 (20%) 27  7% NS
Chronic leukemia 20 1 (5%) 6  6%
MM/NHL/others 51 6 (12%) 14  5%
isease status at SCT†
Advanced 109 19 (17%) 24  5% .05
Early 38 3 (8%) 10  5%
Active disease 90 17 (19%) 26  6% .03
Remission 57 5 (9%) 12  5%
rior SCT within 6 mo
Yes 21 11 (52%) 75  13% <.0001
No 126 11 (9%) 12  4%
rior SCT >6 mo‡
Yes 33 3 (9%) 11  6% NS
No 93 8 (9%) 12  4%
onor§
Matched unrelated 38 10 (26%) 38  11% .02
Matched sibling 109 12 (11%) 9  3%
onditioning
NST 84 14 (17%) 23  6% NS
Ablative 63 8 (13%) 16  5%
BI
Yes 16 1 (6%) 11  10% NS
No 131 21 (16%) 21  4%
cute GVHD grade
II-IV 55 18 (33%) 38  8% .0001
0-I 92 4 (4%) 6  3%
S indicates not signiﬁcant; TBI, total body irradiation; NHL,
non-Hodgkin lymphoma; MM, multiple myeloma.
Survival rates were estimated by the Kaplan-Meier method and
categorical values were compared by using the log-rank test.
Early disease: acute leukemia in ﬁrst remission, CML in ﬁrst
chronic phase, and MM/NHL in ﬁrst remission; advanced dis-
ease; all the rest.
Patients with prior SCT within 6 mo were not included.
Five patients with 1 antigen–mismatched related donors were
included with the matched unrelated group.patients; in most other patients they were attributed
B&MTo other conditions, predominantly hepatic failure.
ever is also most often associated with concomitant
nfections rather than TMA. Even the elements of the
ess strict deﬁnition may be related to other compli-
ations. Thrombocytopenia is common after SCT for
able 3. Proportional Hazards Regression Model for the Occurrence of
hrombotic Microangiopathy after Stem Cell Transplantation*
Variable
TMA Incidence
Hazard Ratio
(95% Confidence
Interval) P Value
ex (male) 1.9 (0.6-5.5) NS
isease status
Advanced 1.1 (0.3-4.3) NS
Active disease 1.8 (0.6-5.3) NS
rior SCT <6 mo 6.4 (2.6-15.9) .001
onor (MUD) 1.6 (0.6-4.1) NS
cute GVHD
(grade III-IV) 14.5 (3.4-61.3) .01
S indicates not signiﬁcant; MUD, matched unrelated donor.
The factors found signiﬁcant in the univariate analysis (Table 2)
were included in a Cox regression model.
able 4. Comparison of Patient Characteristics and Outcomes between
atients after NST and Myeloablative Conditioning
Variable NST Myeloablative P Value
84 63
edian age, y (range) 50 (16-66) 37 (18-65) .003
ex
Male 53 (63%) 34 (54%) NS
Female 31 (37%) 29 (46%)
isease type
Acute leukemia 30 (36%) 46 (73%) .001
Chronic leukemia 12 (14%) 8 (13%)
MM/NHL/others 42 (50%) 9 (14%)
isease status at SCT
Advanced 66 (79%) 43 (68%) NS
Early 18 (21%) 20 (32%)
Active disease 51 (61%) 39 (62%)
Remission 33 (39%) 24 (38%)
rior SCT within 6 mo
Yes 16 (19%) 5 (8%) .06
No 68 (81%) 58 (92%)
onor
Matched unrelated 22 (26%) 22 (26%) NS
Matched sibling 62 (74%) 62 (74%)
cute GVHD grade
II-IV 32 (38%) 24 (38%) NS
III-IV 19 (23%) 16 (25%)
himerism
Complete 50 (60%) 39 (62%) NS
95%-99% donor 7 (8%) 7 (11%)
50%-94% donor 4 (5%) 4 (6%)
Not evaluable* 23 (27%) 13 (21%)
S indicates not signiﬁcant; MM, multiple myeloma; NHL, non-
Hodgkin lymphoma.
Chimerism was evaluated 1 mo after SCT. Not evaluable indicates
patients dying or with disease progression before chimerism
testing and patients with nonengraftment or missing data.
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4ultiple reasons, such as delayed engraftment,
VHD, infections, CMV infection, and drugs. De-
ayed platelet engraftment is common after unrelated
onor SCT. In most studies, as also observed in our
tudy, as many as 50% of all patients with TMA did
ot have platelet engraftment at the time of onset of
MA, such that declining platelet count could not be
ocumented. Similarly, TMA may overlap with cyclo-
porine toxicity, and fragmented red blood cells are
ften observed in blood ﬁlms of patients treated with
yclosporine [20,29]. However, a markedly increased
DH level is more speciﬁc and should always raise
uspicion for TMA [9].
able 5. Patient Treatment and Outcome
Patient
No. TMA Type
Treatment
CSA
Plasma
Infusion
1 Classic Reduced Yes
2 Classic DC Yes
3 Classic DC Yes
4 Classic Reduced No
5 Classic Reduced Yes
6 Classic DC Yes
7 Classic DC Yes
8 Classic/hepatic DC Yes
9 Classic/hepatic Reduced Yes
10 Hepatic Reduced Yes
11 Hepatic Reduced Yes
12 Hepatic Reduced Yes
13 Hepatic Reduced Yes
14 Hepatic DC Yes
15 Hepatic DC Yes
16 Hepatic/2allo Off at diagnosis Yes
17 Hepatic/2allo Reduced Yes
18 Hepatic/2allo Off at diagnosis Yes
19 2allo Off at diagnosis Yes
20 2allo Reduced Yes
21 2allo DC Yes
22 2allo Off at diagnosis Yes
C indicates discontinued; TPE, therapeutic plasma exchange; d
remission; PR, partial response; NR, no response; CSA, cyclosp
igure 3. Overall survival after the diagnosis of thrombotic mi-
aroangiopathy after allogeneic stem cell transplantation.
90In this study, we identiﬁed 3 clinical settings for
he occurrence of SCT-associated TMA with some
verlap: a classic SCT-associated TMA, TMA associ-
ted with severe hepatic GVHD, and TMA associated
ith a second allogeneic SCT. We determined a sep-
rate clinical setting for patients who had a second
llogeneic SCT. These patients were given intensive
hemotherapy followed by granulocyte colony-stimu-
ating factor–mobilized lymphocytes and stem cells.
he major difference from the classic variant is that
yclosporine was not administered after SCT. There
as some overlap with the hepatic GVHD variant,
ecause some patients in this group had severe
VHD before the diagnosis of TMA. The classic
ultifactorial TMA occurred with an estimated risk of
%  3%, which is very similar to the risk in other
arge case series. The excess TMA risk in this study
as attributed to the other 2 clinical settings.
The identiﬁcation of risk factors for the occur-
ence of TMA will conceivably allow early diagnosis
nd, perhaps, the timely introduction of therapeutic or
reventive measurements. In this study, multivariate
nalysis determined that the occurrence of acute
VHD and a second SCT within 6 months were the
ajor predictors of TMA, with a hazard ratio of 14.5
nd 6.4, respectively. Univariate analysis also sug-
ested that SCT from an unrelated donor and during
Response OutcomeTPE
No CR Died of chronic GVHD day 227
Yes PR Died of relapse day 69
No NR Died of DAH day 58
No NR Died of DAH day 29
No CR Alive and well day 152
No CR Died of relapse day 196
Yes NR
defib NR
Died of cerebral TMA day 84
Yes NR Died of acute GVHD day 29
No NR Died of acute GVHD and DAH day 2
No NR Died of acute GVHD and DAH day 3
No NR Died of acute GVHD day 5
No NR Died of acute GVHD day 4
No NR Died of acute GVHD day 13
No NR Died of CNS bleeding day 13
No NR Died of chronic GVHD day 21
No NR Died of acute GVHD day 26
No NR Died of acute GVHD day 22
Yes CR Alive day 317
No NR Died of DAH day 7
No CR Alive day 96
No NR Died of DAH day 17
No PR Alive day 92
ﬁbrotide; 2allo, second allogeneic transplantation; CR, complete
.eﬁb, dedvanced or active disease might predict TMA (Table
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B), but these factors did not remain statistically signif-
cant in the multivariate model (Table 3). Most studies
ave shown that SCT from unrelated donors carries a
igher risk for TMA [8,9,11,12]. Some studies
8,9,14,15] have shown that female sex is a risk factor,
ut other studies did not support this association
5,11,13,15]. Similarly, older age was found as a risk
actor in some [9], but not all [11-13], studies. Acute
VHD is considered a major risk factor for TMA in
ome studies [5,7,8,12,15,20], but not others [8,11,13].
orticosteroid treatment increases the risk of TMA
13,16]. Some researches have suggested not including
atients with severe GVHD in TMA studies [12]
ecause they usually do not respond to TPE. How-
ver, most studies have included these patients be-
ause GVHD may have a role in the pathogenesis of
MA. These patients may not beneﬁt from current
vailable therapy [12], but they may beneﬁt from fu-
ure therapies and therefore should not be excluded.
n this series, patients with severe hepatic GVHD had
73%  14% risk of developing TMA. TMA is
robably underdiagnosed in this setting because of the
omplicated and terminal status of patients in this
ondition. Only a few reports suggest an association of
econd SCT with TMA [7,9]. Our study included a
elatively large number of allogeneic SCTs after fail-
re of an autologous or allogeneic SCT (Tables 1 and
). When this SCT was given within 6 months of the
urrent allogeneic SCT, the projected risk of TMA
as 75%  13% (Table 2).
The pathogenesis of SCT-associated TMA is
omplicated and multifactorial. An intense condition-
ng regimen is considered to have a role in the patho-
enesis of TMA by inducing endothelial cell damage.
otal body irradiation during conditioning was found
o be a risk factor for TMA in some studies [30,31] but
ot in others [8,9,11,13]. There are very few data on
he occurrence of TMA after nonmyeloablative con-
itioning [7,32,33]. Elliot et al. [7] reported 2 cases of
MA among 13 NST recipients (15.4%); both had a
rior autologous SCT. This was higher than after
tandard ablative conditioning in that study. Similarly,
n this study, 14 of 84 NSTs were complicated with
MA (Table 2). The multivariate analysis did not
etermine that the use of less intensive conditioning
onferred a lesser risk for TMA. If one assumes that
MA is initiated by the toxicity of the conditioning
egimen, this unexpected observation may occur be-
ause the beneﬁcial effects of reduced toxicity are
ffset by other factors that increase that risk. This
elates in part to the selective use of NST in older and
ore debilitated patients, in patients with a second
CT or extensive prior therapy, and after unrelated
onor SCT—all of these are risk factors for TMA.
GVHD is another major risk factor for TMA.
hen reduced-intensity regimens were introduced, it
as hoped that GVHD rates would decrease [25]. The p
B&MTathogenesis of GVHD involves cytokine release that
s associated with the tissue injury induced by the
onditioning regimen [34], and it was assumed that
imitation of tissue injury would limit GVHD. Also,
he mixed chimerism often detected after NST was
hought to be able to limit GVHD [26]. With time it
as appreciated that GVHD rates were not decreased;
ather, GVHD may be delayed throughout the course
35]. Also, with the use of reduced-intensity regimens
uch as the combination of ﬂudarabine and busulfan
r melphalan, as we used in most NSTs in this study,
ost patients achieve complete chimerism early after
CT (similarly to ablative SCT) and are not protected
rom GVHD [26]. Indeed, in our study there was no
ifference in chimerism and acute GVHD rates be-
ween the 2 cohorts (Table 4). Because GVHD may
ave a major role in TMA pathogenesis, the inability
o limit its incidence and severity with NST may
xplain why TMA is not reduced.
Eissner et al. [36] reported that ﬂudarabine in-
uces apoptosis, activation, and alloreactivity of hu-
an endothelial cells and also causes damage to der-
al and alveolar epithelial cells. Fludarabine is a major
onstituent of nonmyeloablative conditioning, and the
ffect of ﬂudarabine on endothelial cells may con-
ribute to the pathogenesis of TMA after NST. As
iscussed previously, acute GVHD is probably as
ommon after NST as after standard ablative condi-
ioning, and as reported by Eissner et al. [36], the
ndothelial cells may become a common target for
VHD after ﬂudarabine therapy. It is interesting to
ote that deﬁbrotide was found to be protective
gainst ﬂudarabine-related damage in that study.
here are initial reports that deﬁbrotide, a ﬁbrinolytic
gent used for the treatment of veno-occlusive disease
f the liver (VOD) [37], may be a promising treatment
or SCT-associated TMA [38]. There is a rationale for
xploring the use of deﬁbrotide in SCT with a high
isk of TMA, such as second SCTs and those from
nrelated donors, especially after ﬂudarabine-contain-
ng conditioning regimens.
SCT-associated TMA has been associated with
isseminated fungal infections or viral infections, most
requently CMV [5,7,9,12]. In this study, only 1 pa-
ient had documented fungal infection at the time of
iagnosis. Although many patients had CMV reacti-
ation during the course, it could not be related to the
ime of diagnosis.
The introduction of TPE dramatically changed
he prognosis of patients with idiopathic TMA, with
ery high response rates. However, the treatment of
CT remains controversial. In particular, there are
ontroversial data as to whether TPE is effective in
his setting [39-41]. In this study, the ﬁrst measure-
ent was usually a reduction of cyclosporine dose and
lasma infusion, with a response rate of 23%. Four
atients of the nonresponders had TPE, and 2 had
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4artial or complete responses. Overall, 32% re-
ponded. It can be concluded that TPE may have a
ole in SCT-associated TMA. However, because of
he complexity of the patients and questionable efﬁ-
acy, TPE may not necessarily be introduced as the
rst therapeutic strategy.
The occurrence of TMA carried an ominous
rognosis. Only 4 patients remain alive, and the
aplan-Meier estimate of long-term survival is less
han 10%. There was a wide variability in the reported
ortality in patients with SCT-associated TMA,
anging from 31% to 100%. However, the estimated
ortality was 84% for patients with 2 or 3 of the
ollowing criteria: TMA within 120 days of SCT, use
f cyclosporine, and renal or neurologic symptoms [6].
ost patients in our study belonged to this high-risk
roup. Similarly to other studies, most patients died of
nrelated causes, such as GVHD and relapse. TMA
as the principal or contributing cause of death in 8
atients (36%), 1 patient died of cerebral TMA and
efractory convulsions, and 5 patients died of bleeding
omplications (Table 5). It is interesting to note that 6
atients with TMA also had DAH. The association of
MA with VOD has been reported in a few studies
5,8,15], suggesting that both syndromes, which may
nvolve small-vessel injury, share the same pathogen-
sis. The incidence of VOD in our study was very low
ecause of the use of nonmyeloablative conditioning
nd intravenous busulfan in most patients [42], there-
ore not allowing documentation of this association.
he association of TMA and DAH has been reported
efore in only 1 study [43]. Four patients with TMA
nd DAH were given ﬂudarabine-containing condi-
ioning, and, as suggested previously, ﬂudarabine can
ause endothelial and pulmonary epithelial damage
36]. The association of GVHD, VOD, TMA, and
AH may be related to the cytokine release cascade
riggered by endothelial damage [7,10]. The increased
evel of inﬂammatory cytokines and T-cell activation
n unrelated donor SCT explains the higher risk for
hese complications in this setting.
In conclusion, SCT-associated TMA remains a
elatively common complication with unsatisfactory
herapy and a grim prognosis. The use of ﬂudarabine-
ased reduced-intensity conditioning does not confer
lesser risk of TMA. Further exploration of novel
herapeutic interventions and use of preventive mea-
urements in high-risk patients are required.
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